Keros Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
All right. Good afternoon, everyone, and thanks for joining us here at the SVB Securities Global Biopharma Conference. My name is Tom Smith. I'm one of the senior biotech analyst here at SVB Securities, and very happy to be hosting this next fireside chat with Keros Therapeutics. As a company with deep expertise in TGF-beta biology, three clinical stage assets, and a number of really interesting intrinsic and extrinsic data catalysts expected over the next 12 months that I'm sure we'll get into in more detail here.
Joining us from the company is CEO, Jas Seehra.
Jas, thanks for joining us.
Tom, thanks for this invitation to speak today, as always. I'm excited to share the progress that we're making on our programs and answer any questions that you have.
Excellent. All right. Maybe just one quick housekeeping point here for investors that are joining us via the webcast. You can either
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
